We, FDA, are issuing this guidance to provide you, establishments that collect Whole Blood or blood components intended for transfusion or for further manufacture, including Source Plasma and Source Leukocytes, with recommendations for a requalification method under Title 21 of the CFR.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/33UYk0P
No comments:
Post a Comment